Impact of New CLSI Guidelines on Antibiotic Susceptability Pattern

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2011 by University of Southern Nevada.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
University of Southern Nevada
ClinicalTrials.gov Identifier:
NCT01352377
First received: May 10, 2011
Last updated: NA
Last verified: April 2011
History: No changes posted
  Purpose

Assessing the precise MIC for the Ceftriaxone using E-test. To determine what proportion of susceptibility reports will be reclassified based on the new CLSI guidelines.Antibiotic susceptibility reports of blood cultures, urine cultures,aseptic body fluid cultures growing Enterobacteriaceae organism generated by the Phoenix machine will be obtained on a daily basis.MIC for Ceftriaxone will be noted.If the MIC is <=2 for Ceftriaxone,those cultures would be used to run an additional test - E- test.E-test gives us more precise MIC values compared to Phoenix machine.We will analyze the data collected over 2 months. We will determine the proportion of susceptibility reports reclassified based on the new CLSI guidelines.


Condition
Antibiotic Susceptibility Patterns

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: A STUDY ASSESSING THE IMPACT OF THE NEW CLSI GUIDELINES ON ANTIBIOTIC SUSCEPTABILITY TESTING PATTERNS

Resource links provided by NLM:


Further study details as provided by University of Southern Nevada:

Estimated Enrollment: 50
Study Start Date: May 2011
Estimated Study Completion Date: July 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Age more than 21 years who are inpatients at UMC.

Criteria

Inclusion Criteria:

  • Antibiotic susceptibility reports of blood cultures, urine cultures,aseptic body fluid cultures growing Enterobacteriaceae organism generated by the Phoenix machine.

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01352377

Locations
United States, Nevada
Umc
Las Vegas, Nevada, United States, 89102
Sponsors and Collaborators
University of Southern Nevada
  More Information

No publications provided

Responsible Party: Alan Greenberg, UMC
ClinicalTrials.gov Identifier: NCT01352377     History of Changes
Other Study ID Numbers: P20 RR-016464
Study First Received: May 10, 2011
Last Updated: May 10, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Disease Susceptibility
Disease Attributes
Pathologic Processes
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Antitubercular Agents

ClinicalTrials.gov processed this record on August 01, 2014